Celebrex May Reduce Levels of Lung Cancer... (ssor of medicine at City of Hope Cancer ...)

Celebrex May Reduce Levels of Lung Cancer Biomarker

Date:6/1/2008

ssor of medicine at City of Hope Cancer Center in Duarte, Calif.

Lung cancer is a notoriously difficult-to-treat disease, largely because it's usually not caught in its early stages.

"Lung cancer is an extraordinarily challenging tumor type," confirmed Dr. Howard Sandler, moderator of the news conference and a professor of radiation oncology and urology at the University of Michigan.

Prevention, therefore, becomes key. Quitting smoking or never smoking, of course, greatly reduces the risk for this disease. But there are people who beat the odds even if they smoke, just as there are nonsmokers who do develop lung cancer.

"We need to continue to refine what a high-risk population is, both clinical and biological characteristics, and that leads us into biomarkers," Kim said. The researchers were primarily interested in how Celebrex might affect Ki-67, a protein that may be related to cell proliferation.

The cox-2 enzyme is expressed in both precancerous lesions in lung tissue, as well as in lung cancer, and it has an inflammatory aspect that can stimulate more cell growth within the lung.

This study involved more than 200 patients, all of whom had a history (current or prior) of a greater than 20-pack-years cigarette habit. All participants underwent biopsies at the opening of the study, at three months and again at six months.

They were then randomized to take either Celebrex or a placebo for three months, after which they either continued on that course or switched to the other arm.

Over three months, high-dose Celebrex (400 milligrams twice a day) did reduce expression levels of Ki-67, as well as the cox-2 enzyme and a third biomarker, NF-kappa-B.

The effect was seen in both current and former smokers but was stronger in current smokers, Kim said.

No cardiac side effects were seen in the group, although previous research showed a benefit to Celebrex in reducing colon
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Celebrex-Lipitor combo may halt prostate cancer
2. Celebrex Plus Lipitor Could Fight Prostate Cancer
3. Celebrex, Naproxen Wont Prevent Mental Decline
4. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
5. New study: Pine bark reduces perimenopausal symptoms
6. Different method of evaluating the urinary tract system reduces radiation dose
7. Saline Reduces Mortality for Brain Injury Patients
8. New approaches to reduce scarring
9. Fruity vegetables and fish reduce asthma and allergies
10. New study: Pine bark extract reduces ADHD symptoms in children
11. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction

Post Your Comments:

(Date:12/15/2009)... Study examines potential for injury when doctors decide benefits ... (HealthDay News) -- MRI scans can pose a serious ... U.S. Food and Drug Administration researchers exposed pacemakers to ... electrical voltage produced at the tip of the pacemaker ... patient,s heart. , The exposure to MRI magnetic pulses ...

(Date:12/15/2009)... Dec. 15 Accelify is proud to announce ... of Advisors. David will serve as Director of Development ... Accelify,s National Board of Advisors. ,, David ... District,s Board of Education in June 1995. As the ... of over 600,000 stretching from Northeast Los Angeles through ...

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. ... globally or complete a product portfolio they also ... safety programs. ,, A new free, white paper ... a Hearing Conservation Program: US Airways ," details ... West led the newly formed company to enhance ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...

(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...

[0] Patients With Pacemakers Should Avoid MRI Scans [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs

... is an early or predisposing event in the pathogenesis ... research which appears online on September 23 in the ... Myelodysplastic syndrome is a heterogeneous group of diseases ... hematopoietic lineages, clonal evolution and a tendency to progress ...

... been used widely in the treatment of hypertension ... hypertension guidelines. Moreover, after myocardial infarction and in ... blockers prevents re-infarction, hospitalisation for heart failure, and ... that atenolol is not very effective in hypertension. ...

... of bleeding from solid abdominal organs has been traditionally ... which has latelybeen recognized as detrimental. // Although there ... hemorrhage, bleeding is still the direct cause of death ... ,There is a continuous search for the "magical drug" ...

... has produced two Anti-retrovirals which can be used ... Nevirapine and Zidovudine is produced by CMSI in ... two drugs were officially released by Sebastian Ouseperamppil, ... which could maintain the quality control and Research ...

... Reddy Union Minister of Information, Broadcasting and Culture, India ... public regarding the prevention and treatment of HIV infections. ... social relevance. The media could play an important role ... the different broadcasting tools such as radio, websites, SMS, ...

... study, published in the October issue of the journal ... immune system abnormalities, including reduced levels of NKT cells, ... cells in the liver regulate production of cytokines, which ... may contribute to obesity -related liver disease. ,The ...

Other Medicine News:Health News:Evidence against use of Beta blockers as first choice in the treatment of primary hypertension 2 Health News:Aprotinin in the treatment of hemorrhagic shock trauma patients 2 Health News:Obesity As A Contributor To Liver Disease 2

Chronic Exposure To Benzene May Result In Dysplasia Evidence against use of Beta blockers as first choice in the treatment of primary hypertension Aprotinin in the treatment of hemorrhagic shock trauma patients CMSI produces Low cost Anti-retroviral drugs in India Indian Minister wanted Media to Propaganda HIV/AIDS awareness Obesity As A Contributor To Liver Disease

(Date:12/15/2009)... CLEVELAND, Dec. 15 At today,s regular meeting ... (NYSE: LZ ), the board declared a ... March 10, 2010 to holders of record at the ... About The Lubrizol Corporation ,, The Lubrizol Corporation ... chemical company that produces and supplies technologies that improve ...

(Date:12/15/2009)... Today, Hill-Rom Holdings, Inc. (NYSE: HRC ... strategic and financial initiatives at its Investor Conference ... hosted by Peter H. Soderberg, president and CEO ... following topics: ,, Status of multi-year strategic ... financial updates Smart technologies that interface with ...

(Date:12/15/2009)... Rib-X Pharmaceuticals, Inc., a company focused ... drugs for the treatment of serious multi-drug-resistant infections ... research agreement with Massachusetts General Hospital (MGH). ... collaboration, Dr. David Hooper of MGH will evaluate ... model to determine resistance development and to validate ...

Breaking Medicine Technology:Lubrizol Declares Dividend 2 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7 Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2 Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3 Smart Post Brings Scrubs 26amp 3B Beyond to Canadian Doorsteps 60656 1 Smart Post Brings Scrubs 26amp 3B Beyond to Canadian Doorsteps 60656 2 Gastroenterology hepatology societies release report evaluating fellowship training curriculum 60651 1 Gastroenterology hepatology societies release report evaluating fellowship training curriculum 60651 2 Gastroenterology hepatology societies release report evaluating fellowship training curriculum 60651 3 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 1 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 2 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 3 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 4

[0] Lubrizol Declares Dividend [0] Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies [0] Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital

... for XIENCE V with No,Late Stent Thrombosis ... Three Years, BARCELONA, Spain, May 22, 2007 ... trial demonstrated no,additional Major Adverse Cardiac Events ... treated with either Abbott's XIENCE(TM) V,Everolimus Eluting ...

... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...

Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2 Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3 Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9

Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

Joseph Double Hook 10 mm wide. Designated most popular model or size....

Exceptional comfort, handling and eye health with a convenient replacement schedule. Suitable for wearers seeking the ideal combination of convenience and performance in a planned replacement soft le...

The proven daily wear spherical soft contact lens....

Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...

Medicine Products:

Joseph Double Hook Frequency 55 Sphere Cibasoft Acuvue2

Celebrex May Reduce Levels of Lung Cancer...(ssor of medicine at City of Hope Cancer ...),Health